Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers March 29, 2017
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - March 29, 2017

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

3/29/17 - A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0 [Tehran Times (Iran)]
Along the way, Danos picked up some tailor-made vector tech at Regenxbio. On Monday, he was the new CSO at Regenxbio. And while hes left Biogen, hell be working more closely than ever with Wilson, the scientific founder of Regenxbio and another high profile groundbreaker in the field who helped create the gene therapy vectors that Regenxbio has bee
3/29/17 - Many doctors clueless on diabetes treatment - NewsDay Zimbabwe [NewsDay (Zimbabwe)]
MANY doctors in Southern African are clueless on the proper treatment of diabetes, resulting in some patients getting wrong medication and dosages, the head of an international pharmaceutical company has said. Speaking at Harare Central Hospital yesterday, Novartis South Africa president Thomas Kowallik pledged to work with the Zimbabwe Diabetic...
3/29/17 - A1M Pharma: ROSGard? shows strong protective effect against renal damage in connection with radiation therapy in a preclinical long-term study
Preliminary data from the completed preclinical long-term study with an animal model clearly establish the strong protective effect against renal damage of the active substance in the candidate drug ROSGard? in connection with radiation therapy. Clinical studies are scheduled to start in the beginning of 2018. A1M Pharma has therefore conducted t
3/29/17 - Acorda Announces Long-Term Safety Data for CVT-301
Acorda Therapeutics, Inc. today announced results from two ongoing, long-term safety studies of CVT-301 in people with Parkinson s that showed no differences in pulmonary function between the group receiving CVT-301 and an observational control group. These results are consistent with previously reported data from Phase 2 b and Phase 3 clinical
3/29/17 - Ajay Verma, M.D., Ph.D. Joins the Top Ranks of United Neuroscience to Help Tackle Global Neurodegeneration
Dr. Verma joins the United Neuroscience team from Biogen, where he helped spark neurodegeneration therapeutic efforts by building disease area strategy, clinical development teams, experimental medicine capabilities, novel imaging technologies and a neurology drug development fellowship program in conjunction with Massachusetts General Hospital.
3/29/17 - Alexion appoints biopharma veteran Hantson CEO [News Central Asia]
New Haven-based Alexion Pharmaceuticals Inc. on Monday appointed a bioscience industry veteran, who was most recently president and CEO of blood-disorder drugmaker Baxalta, as its new chief executive officer. Ludwig N. Hantson will take over Alexion`s top job immediately, following the sudden departure in December of its former CEO, David Hallal, w
3/29/17 - Allergan, Paratek hit late-stage acne goals, prep for sarecycline NDA [Syrian Arab News Agency]
Allergan and partner Paratek Pharmaceuticals have hit their primary endpoints in two key phase 3 acne trials for their investigational med sarecycline. The pair will now seek an FDA NDA in the second half of the year after the two replicative late-stage tests that saw the med outdo placebo in treating inflammatory acne lesions in subjects with mode
3/29/17 - Analyst Activity Piper Jaffray Companies Reiterates Overweight on Cara Therapeutics (NASDAQ:CARA)
Analyst Ratings For Cara Therapeutics (NASDAQ:CARA) Today, Piper Jaffray Companies reiterated its Overweight rating on Cara Therapeutics (NASDAQ:CARA) with a price target of $23.00. There are 9 buy ratings on the stock. The current consensus rating on Cara Therapeutics (NASDAQ:CARA) is Buy (Score: 3.00) with a consensus target price of $26.40 per s
3/29/17 - AP Top Health News at 2:45 a.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 5:54 a.m. EDT
Somalia's drought once again has thousands on the move Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP
3/29/17 - AP Top Health News at 8:05 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - AP Top Health News at 8:16 p.m. EDT
Brain and arm implants help paralyzed US man feed himself ACLU asks Ohio city to stop charging drug overdose survivors Senate, White House pass on House push to revive health bill Democratic senator asks drugmakers about opioid sales plans States push to protect birth control despite failed GOP bill FDA approves 1st drug for moderate& severe eczema
3/29/17 - APCER Life Sciences Launches Quality Assurance Auditing and Consultancy Services
New offering meets growing demand for expertise in compliance across pharmaceutical companies' clinical and post-marketing ecosystem LONDON, March 29, 2017 APCER Life Sciences, the truly global provider of safety, medical, regulatory and technology services, announced today that it will now offer Quality Assurance Auditing as a stand-alone servic
3/29/17 - ARMO BioSciences Announces First Patient Dosed in Pivotal Phase 3 Trial of Immunotherapy AM0010 for Advanced Pancreatic Cancer
ARMO BioSciences, Inc., a clinical-stage immuno-oncology company, announced that the first patient has been dosed in the Company's international Phase 3 pivotal clinical trial to evaluate its lead investigational immuno-oncology drug AM0010 in combination with FOLFOX as second-line treatment for patients with advanced pancreatic cancer.
3/29/17 - AstraZeneca Gets Priority Review By US Of LYNPARZA For Ovarian Cancer
LONDON- AstraZeneca PLC's new drug application for LYNPARZA tablets for use in platinum-sensitive, relapsed ovarian cancer patients in the maintenance setting has been accepted for priority review by the US Food& Drug Administration- with a decision expected in the third quarter 2017.. In clinical trials, LYNPARZA demonstrated a median Progression
3/29/17 - Bharat Book Bureau: Global Over-the-Counter (OTC) Drugs and Dietary Supplements Markets
The global market for over the counter drugs and dietary supplements reached $164.7 billion in 2016 and should reach $220.8 billion in 2021, with a compound annual growth rate of 6.0%. The study goal of this report is to understand the OTC drugs and dietary supplement market and provide five-year forecasts for the same. The objective of the study i
3/29/17 - Bharat Book Bureau: Infectious Disease Drugs The Chinese Market
The Chinese infectious disease drug market is big, fast-growing and dominated by brands from outside China. This market is very important for pharmaceutical companies in North America, Europe and other developed regions that look for strong growth and high profits in the following decade. The goal of this study is to help readers achieve a comprehe
3/29/17 - British new lung cancer drug wins approval in China [Philippines News Agency]
The London stock market listed company AstraZeneca Monday announced that the China Food and Drug Administration has granted marketing authorization for its lung cancer pill Tagrisso in China. Tagrisso is designed for the treatment of adult patients with certain genetic mutations, which is the first AstraZeneca medicine approved under the CFDA's...
3/29/17 - Center Point Clinical Services' Studies Show That Pharmacist-led Interventions Increase Clinical Trial Patient Medication Adherence and Compliance and Provide Robust Study Data
Center Point Clinical Services, creator of the world's first Siteless CRO platform, announced today study results presented in two separate posters at the Academy of Managed Care Pharmacy,# AMCP2017, Managed Care and Specialty Pharmacy annual meeting in Denver, Colorado. Joe Martinez, CEO of Center Point Clinical Services and the lead author of bot
3/29/17 - ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors [National News Agency (Lebanon)]
Mr. Rubin, age 56, has served as OPKO Health, Inc.s Executive Vice President Administration since May 2007 and as a director of since February 2007. Mr. Rubin currently serves on the board of directors for the following companies: VBI Vaccines Inc., a commercial-stage biopharmaceutical company developing a next generation of vaccines; Cognit, Inc.,
3/29/17 - Data from Yang Ming National University Advance Knowledge in Neurodegenerative Diseases and Conditions (Conductive nanogel-interfaced neural...
By a News Reporter-Staff News Editor at Biotech Week Fresh data on Neurodegenerative Diseases and Conditions are presented in a new report. According to news reporting originating from Taipei, Taiwan, by NewsRx correspondents, research stated, "Chronic brain stimulation has become a promising physical therapy with increased efficacy and efficienc
3/29/17 - DaVita Clinical Research Wins 2017 CRO Leadership Awards
DaVita Clinical Research, a specialty contract research organization with services spanning the full spectrum of drug and device development, has been recognized by Life Science Leader in multiple award categories of its 2017 CRO Leadership Awards. "DCR is devoted to its customers and committed to becoming the service provider of choice," said A
3/29/17 - DrugDev Continues Robust Growth in Europe, Attracts Veteran Pharmaceutical Industry Senior Executive George Masoura as Vice President of Business...
DrugDev's global focus and expertise is reflected in its experience working with 85 sponsors and CROs on more than 1,800 clinical trials. With study team and site users in 60 countries, DrugDev leads the industry in geographical scale with US $2 billion paid to sites in 37 currencies, over 17,000 clinical trial agreement contracts successfully nego
3/29/17 - Egalet Announces U.S. Food and Drug Administration Does Not Object to Egalet's Distribution of Materials and Communications to Healthcare Professionals Regarding Abuse-Deterrent Properties of ARYMO? ER via Intranasal Route
Egalet Corporation, a fully integrated specialty pharmaceutical company focused on developing, manufacturing and marketing innovative treatments for pain and other conditions, today announced the U.S. Food and Drug Administration does not object to Egalet's distribution of promotional materials and communications to healthcare professionals...
3/29/17 - Enrollment Commences in Phase III Clinical Study of Eisai's Bace Inhibitor Elenbecestat in Early Alzheimer's Disease in Japan
TOKYO, Mar 29, 2017 Eisai Co., Ltd. announced today that enrollment has commenced in Japan for MISSION AD1, a global Phase III clinical study of the in-house developed oral beta secretase cleaving enzyme inhibitor elenbecestat in patients with early Alzheimer's disease. The Phase III clinical trial program for elenbecestat consists of two global
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415